2005
DOI: 10.1086/430837
|View full text |Cite
|
Sign up to set email alerts
|

Occurrence of Thrombocytopenia in Plasmodium vivax Malaria

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
17
1
1

Year Published

2006
2006
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(24 citation statements)
references
References 19 publications
5
17
1
1
Order By: Relevance
“…In our study we found moderate and severe thrombocytopenia to be statistically significant among P. vivax malaria patients and this observation supports previous reports in isolated literature pertaining to thrombocytopenia in vivax malaria [19,20,21]. Thrombocytopenia has been postulated to occur secondary to peripheral destruction, splenic sequestration, and platelet consumption secondary to DIC, but none of our patients showed any bleeding tendencies despite very low platelet counts.…”
Section: Discussionsupporting
confidence: 90%
“…In our study we found moderate and severe thrombocytopenia to be statistically significant among P. vivax malaria patients and this observation supports previous reports in isolated literature pertaining to thrombocytopenia in vivax malaria [19,20,21]. Thrombocytopenia has been postulated to occur secondary to peripheral destruction, splenic sequestration, and platelet consumption secondary to DIC, but none of our patients showed any bleeding tendencies despite very low platelet counts.…”
Section: Discussionsupporting
confidence: 90%
“…In this tropical epidemiological scenario, clinical studies addressing that topic would also be useful, given that few studies in the country have assessed the epidemiology of severe P. vivax malaria [11,32], which has been largely documented and reported in other countries of Latin America, such as Venezuela [33][34][35] and Brazil [36][37][38], as well in Asia [39][40][41].…”
Section: Discussionmentioning
confidence: 99%
“…The patient presented here was treated for his malaria with 1 g atovaquone/400 mg proguanil hydrochloride (Malarone, GlaxoSmithKline; Research Triangle Park, NC) daily for 3 consecutive days, along with primaquine 30 mg base daily for 14 days, and he had a prompt clinical response. His exceptionally profound thrombocytopenia was attributed to immune-mediated thrombocytopenic purpura, which is a known complication of malaria (although more typically P. falciparum and, to a lesser extent, P. vivax 28 ), and his platelet count rapidly normalized after treatment with intravenous immune globulin.…”
Section: Resultsmentioning
confidence: 99%